These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2643996)

  • 1. Acute and subchronic effects of low-dose bromocriptine in haloperidol-treated schizophrenics.
    Gattaz WF; Rost W; Hübner CK; Bauer K
    Biol Psychiatry; 1989 Feb; 25(3):247-55. PubMed ID: 2643996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low dose bromocriptine: a study of acute effects in chronic mediated schizophrenics.
    Cutler NR; Jeste DV; Kaufmann CA; Karoum F; Schran HF; Wyatt RJ
    Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(2):277-83. PubMed ID: 6146164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative efficacy of bromocriptine, carbamazepine and cyproheptadine with neuroleptics in 24 refractory chronic schizophrenic patients].
    Llorca PM; Wolf MA; Lançon C; Bougerol T
    Encephale; 1993; 19(5):565-71. PubMed ID: 8306925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
    Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
    Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia.
    Santos JL; Cabranes JA; Vazquez C; Fuentenebro F; Almoguera I; Ramos JA
    Biol Psychiatry; 1989 Aug; 26(4):381-8. PubMed ID: 2669981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haloperidol: therapeutic window in schizophrenia.
    Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
    J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.
    Arvanitis LA; Miller BG
    Biol Psychiatry; 1997 Aug; 42(4):233-46. PubMed ID: 9270900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment.
    Widerlöv E; Lindström LH; Besev G; Manberg PJ; Nemeroff CB; Breese GR; Kizer JS; Prange AJ
    Am J Psychiatry; 1982 Sep; 139(9):1122-6. PubMed ID: 6126127
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment with bromperidol in schizophrenic patients].
    Ellerman LA
    Acta Psiquiatr Psicol Am Lat; 1989; 35(1-2):23-30. PubMed ID: 2634329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlates of rapid neuroleptic response in male patients with schizophrenia.
    Petrie EC; Faustman WO; Moses JA; Lombrozo L; Csernansky JG
    Psychiatry Res; 1990 Aug; 33(2):171-7. PubMed ID: 2243894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of treatment with various doses of haloperidol on the pituitary-gonadal axis in male schizophrenic patients.
    Rinieris P; Hatzimanolis J; Markianos M; Stefanis C
    Neuropsychobiology; 1989; 22(3):146-9. PubMed ID: 2485861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
    Jann MW; Crabtree BL; Pitts WM; Lam YW; Carter JG
    Neuropsychobiology; 1997; 36(1):32-6. PubMed ID: 9211442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haloperidol plasma levels and acute clinical change in schizophrenia.
    Coryell W; Kelly M; Perry PJ; Miller DD
    J Clin Psychopharmacol; 1990 Dec; 10(6):397-402. PubMed ID: 2286709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients.
    Ko GN; Korpi ER; Kirch DG
    J Clin Psychopharmacol; 1989 Jun; 9(3):186-90. PubMed ID: 2661607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide.
    Raptis C; Garcia-Borreguero D; Weber MM; Dose M; Bremer D; Emrich HM
    Acta Psychiatr Scand; 1990 Feb; 81(2):162-7. PubMed ID: 2183543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromocriptine therapy in chronic schizophrenia: effects on symptomatology, sleep patterns, and prolactin response to stimulation.
    Brambilla F; Scarone S; Pugnetti L; Massironi R; Penati G; Nobile P
    Psychiatry Res; 1983 Mar; 8(3):159-69. PubMed ID: 6574535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose bromocriptine in neuroleptic-resistant schizophrenia: a pilot study.
    Wolf MA; Diener JM; Lajeunesse C; Shriqui CL
    Biol Psychiatry; 1992 Jun; 31(11):1166-8. PubMed ID: 1356025
    [No Abstract]   [Full Text] [Related]  

  • 19. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
    Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
    Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective clinical response at low plasma levels of haloperidol in Japanese schizophrenics with acute psychotic state.
    Jibiki I; Kubota T; Fujimoto K; Sakamoto H; Hasegawa M; Furuta H; Yamaguchi N
    Jpn J Psychiatry Neurol; 1993 Sep; 47(3):627-9. PubMed ID: 8301878
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.